Impairment of endothelium-independent vasodilation in patients with hypercalcemia

Cardiovascular Research

Volumn 40, Issue 2, 1998, Pages 396-401

  Neunteufl, Thomas ^a   Katzenschlager, Reinhold ^a   Abela, Claudette ^a   Kostner, Karam ^a   Niederle, Bruno ^a   Weidinger, Franz ^a   Stefenelli, Thomas ^a  

^a UNIVERSITY OF VIENNA   (Austria)

Author keywords

Flow mediated dilation; Hypercalcemia; Nitroglycerin induced vasodilation; Primary hyperparathyroidism; Ultrasound; Vascular disease

Indexed keywords

CALCIUM ION; GLYCERYL TRINITRATE; PARATHYROID HORMONE; PHOSPHATE;

ADULT; AGED; ARTERY MEDIA; ARTICLE; ATHEROSCLEROSIS; BLOOD FLOW VELOCITY; CALCIUM BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; FEMALE; HUMAN; HYPERCALCEMIA; MALE; MULTIPLE REGRESSION; PHOSPHATE BLOOD LEVEL; PRIMARY HYPERPARATHYROIDISM; PRIORITY JOURNAL; RISK FACTOR; VASCULAR DISEASE; VASCULAR ENDOTHELIUM; VASCULAR SMOOTH MUSCLE; VASODILATATION;

ADULT; AGED; AGED, 80 AND OVER; BRACHIAL ARTERY; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; HYPERCALCEMIA; HYPEREMIA; HYPERPARATHYROIDISM; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NITROGLYCERIN; OBSERVER VARIATION; REGIONAL BLOOD FLOW; VASODILATION; VASODILATOR AGENTS;

EID: 0032211590     PISSN: 00086363     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0008-6363(98)00177-1     Document Type: Article

References (37)

1. [1] Ronni-Sivula H. The state of health of patients previously operated on for primary hyperparathyroidism compared with rendomized controls. Ann Chir Gynaecol 1985;74:60-65.
2. [2] Palmer M, Adami H-O, Bergström R, Akerström G, Ljunghall S. Mortality after surgery for primary hyperparathyroidism: a follow up of 441 patients operated on from 1956 to 1979. Surgery 1987;102:1-7.
3. [3] Niederle B, Roka R, Woloszczuk W, et al. Successful parathyroidectomy in primary hyperparathyroidism: a clinical follow up study of 212 consecutive patients. Surgery 1987;102:903-909.
4. [4] Christensson T, Hellström K, Wengle B, Alveryd A, Wikland B. Prevalence of hypercalcaemia in a health screening in Stockholm. Acta Med Scand 1976;200:131-137.
5. [5] Palmer M, Adami H-O, Bergström R, et al. Survival and renal function in untreated hypercalcaemia. Population-based cohort study with 14 years of follow up. Lancet 1987;1:59-62.
6. [6] Fleckenstein A, Frey M, Zorn J, Fleckenstein-Grün G. The role of calcium in the pathogenesis of experimental arteriosclerosis. Trends Pharmacol Sci 1987;8:496-501.
7. [7] Roberts WC, Waller BF. Effects of chronic hypercalcaemia on the heart. An analysis of 18 necropsy patients. Am J Med 1981;71:371-384.
8. [8] Slavich GA, Antonucci F, Sponza E. Primary hyperparathyroidism and angina pectoris. Int J Cardiol 1988;19:266-267.
9. [9] Barson AJ, Campbell RHA, Langley FA, Milner RDG. Idiopathic arterial calcification of infancy without intimal proliferation. Virchows Arch 1976;372:167-173.
10. [10] Symons C, Fortune F, Greenbaum RA, Dandona P. Cardiac hypertrophy, hypertrophic cardiomyopathy, and hyperparathyroidism -an association. Br Heart J 1985;54:539-542.
11. [11] Janssens S, DeGeest H, Decramer M. Hypertrophic cardiomyopathy caused by hyperparathyroidism. Report of case and review of the literature. Acta Cardiol 1987;12:287-293.
12. [12] Diamon TH, Kawalsky DL, van der Merwe TL, Myburgh DP. Hypercalcaemia due to parathyroid adenoma and hypertrophic cardiomyopathy. A case report. S Afr Med J 1987;71:448-449.
13. [13] Harnett JD, Parfrey PS, Griffiths SM, et al. Left ventricular hypertrophy in end-stage renal disease. Nephron 1988;18:107-115.
14. [14] Furchgott RF, Zawadzki JV. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 1980;288:373-376.
15. [15] Ross R. The pathogenesis of atherosclerosis: an update. New Engl J Med 1986;314:488-500.
16. [16] Healy B. Endothelial cell dysfunction: an emerging endocrinopathy linked to coronary disease. J Am Coll Cardiol 1990;16:349-356.
17. [17] Meredith IT, Yeung AC, Weidinger FF, et al. Role of impaired endothelium-dependent vasodilation in ischemic manifestations of coronary artery disease. Circulation 1993;87(suppl V):V56-V66.
18. [18] Pohl U, Holtz J, Busse R, Bassenge E. Crucial role of endothelium in the vasodilator response to increased flow in vivo. Hypertension 1986;8:37-44.
19. [19] Holtz J, Förstermann U, Pohl U, Giesler M, Bassenge E. Flow-dependent, endothelium-mediated dilation of epicardial coronary arteries in conscious dogs: effects of cyclooxygenase inhibition. J Cardiovasc Pharmacol 1984;6:1161-1169.
20. [20] Rubanyi GM, Romero JC, Vanhoutte PM. Flow-induced release of endothelium-derived relaxing factor. Am J Physiol 1986;250:H1145-H1149.
21. [21] Lieberman EH, Knab ST, Creager MA. Nitric oxide mediates the vasodilator response to flow in humans (Abstract). Circulation 1994;90((suppl I)):I-138.
22. [22] Joannides R, Haefeli WE, Linder L, et al. Nitric oxide is responsible for flow-dependent dilatation of human peripheral conduit arteries in vivo. Circulation 1995;91:1314-1319.
23. [23] Celermajer DS, Sorensen KE, Gooch VM, et al. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet 1992;340:1111-1115.
24. [24] Celermajer DS, Sorensen KE, Georgakopoulos D, et al. Cigarette smoking is associated with dose-related and potentially reversible impairment of endothelium-dependent dilation in healthy young adults. Circulation 1993;88:2149-2155.
25. [25] Andersen TJ, Uehata A, Gerhard MD, et al. Close relation of endothelial function in the human coronary and peripheral circulations. J Am Coll Cardiol 1995;26:1235-1241.
26. [26] Neunteufl T, Katzenschlager R, Hassan A, et al. Systemic endothelial dysfunction is related to the extent and severity of coronary artery disease. Atherosclerosis 1997;129:111-118.
27. [27] Correti MC, Plotnick GD, Vogel RA. Technical aspects of evaluating brachial artery vasodilatation using high-frequency ultrasound. Am J Physiol 1995;268(Heart Circ Physiol 37):H1397-H1404.
28. [28] Niederle B, Stefenelli T, Glogar D, et al. Cardiac calcific deposits in patients with primary hyperparathyroidism: Preliminary results of a prospective echocardiographic study. Surgery 1990;108:1052-1057.
29. [29] Stefenelli T, Mayr H, Bergler-Klein J, et al. Primary Hyperparathyroidism: Incidence of cardiac abnormalities and partial reversibility after successful parathyroidectomy. Am J Med 1993;95:197-202.
30. [30] Stefenelli T, Abela C, Frank H, et al. Cardiac abnormalities in patients with primary hyperparathyroidism: Implications for follow-up. J Clin Endocrinol Metab 1997;82:106-112.
31. [31] Nickols GA. Actions of parathyroid hormone in the cardiovascular system. Bloodvessels 1987;24:120-124.
32. [32] Smogorzewski M, Zayed M, Zhang YB, Roe J, Massry SG. Parathyroid hormone increases cytosolic calcium concentration in adult rat cardiac myocytes. Am J Physiol 1993;264:H1998-2006.
33. [33] Bogin E, Massry SG, Harary I. Effect of parathyroid hormone on rat heart cells. J Clin Invest 1981;67:1215-1227.
34. [34] Saglikes Y, Massry SG, Iseki K, Nadler JL, Campese VM. Effect of PTH on blood pressure and response to vasoconstrictor agonists. Am J Physiol 1985;248:F674-F681.
35. [35] Nickols GA, Nana AD, Nickols MA, DiPette DJ, Asimakis GK. Hypotension and cardiac stimulation due to the parathyroid hormone-related protein, humoral hypercalcemia of malignancy factor. Endocrinology 1989;125:834-841.
36. [36] Celermajer DS, Sorensen KE, Spiegelhalter DJ, et al. Aging is associated with endothelial dysfunction in healthy men years before the age-related decline in women. J Am Coll Cardiol 1994;24:471-476.
37. [37] Celermajer DS, Sorensen KE, Bull C, Robinson J, Deanfield JE. Endothelium-dependent dilation in the systemic arteries of asymptomatic subjects relates to coronary risk factors and their interaction. J Am Coll Cardiol 1994;24:1468-1474.